Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The deficiency of hepcidin, the hormone that controls iron absorption and its tissue distribution, is the cause of iron overload in nearly all forms of hereditary hemochromatosis and in untransfused iron-loading anemias. In a recent study, we reported the development of minihepcidins, small drug-like hepcidin agonists. Here we explore the feasibility of using minihepcidins for the prevention and treatment of iron overload in hepcidin-deficient mice. An optimized minihepcidin (PR65) was developed that had superior potency and duration of action compared with natural hepcidin or other minihepcidins, and favorable cost of synthesis. PR65 was administered by subcutaneous injection daily for 2 weeks to iron-depleted or iron-loaded hepcidin knockout mice. PR65 administration to iron-depleted mice prevented liver iron loading, decreased heart iron levels, and caused the expected iron retention in the spleen and duodenum. At high doses, PR65 treatment also caused anemia because of profound iron restriction. PR65 administration to hepcidin knockout mice with pre-existing iron overload had a more moderate effect and caused partial redistribution of iron from the liver to the spleen. Our study demonstrates that minihepcidins could be beneficial in iron overload disorders either used alone for prevention or possibly as adjunctive therapy with phlebotomy or chelation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“we tested the therapeutic effect of minihepcidin PR73 (a synthetic hepcidin agonist, Figure S5) in Hamp1−/− mice. We used minihepcidin because it has greater potency and longer lasting effect than full-length hepcidin (Ramos et al., 2012).”
From Hepcidin-Induced Hypoferremia Is a Critical Host Defense Mechanism against the Siderophilic Bacterium Vibrio vulnificus (2015) · cites this paper as Ramos et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Minihepcidins are synthetic hepcidin agonists previously shown to bind ferroportin and induce its endocytosis and proteolysis, thus preventing iron overload in hepcidin-deficient mice (Preza et al., 2011; Ramos et al., 2012).”
From Hepcidin-Induced Hypoferremia Is a Critical Host Defense Mechanism against the Siderophilic Bacterium Vibrio vulnificus (2015) · cites this paper as Ramos et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, administration of a hepcidin analogue, which lacks the β-defensin motif required for its antimicrobial activity (37), rescued the phenotype of hepcidin-deficient mice (Figure 7, C and D).”
From Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia (2017) · cites this paper as [37]
Experimental — accuracy not yet measuredIn the citing paper
“Treatment with an engineered mini-hepcidin mimetic (PR65) prevented iron overload in iron-depleted hepcidin-deficient Hamp−∕− mice, but was less efficient in correcting iron traffic when these mice were already iron overloaded (Ramos et al., 2012).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Ramos et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
Self-citationGanz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Self-citationBasal Insulin Therapy in Type 2 Diabetes
Rosenstock, J., Schwartz, S. L., Clark, C. M., Park, G. D., Donley, D. W., & Edwards, M. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.631 · Cited by 478
Hepcidin and disorders of iron metabolism
Ganz, T., & Nemeth, E. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-050109-142444 · Cited by 466
Self-citationLiver iron concentrations and urinary hepcidin in -thalassemia
Origa, R., Galanello, R., Ganz, T., Giagu, N., Maccioni, L., Faa, G., & Nemeth, E. (2007) · Haematologica · doi:10.3324/haematol.10842 · Cited by 365
Self-citationTargeted disruption of the hepcidin 1 gene results in severe hemochromatosis
Lesbordes-Brion, J.-C., Viatte, L., Bennoun, M., Lou, D.-Q., Ramey, G., Houbron, C., Hamard, G., Kahn, A., & Vaulont, S. (2006) · Blood · doi:10.1182/blood-2006-02-003376 · Cited by 257
Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice
Ramos, E., Kautz, L., Rodriguez, R., Hansen, M., Gabayan, V., Ginzburg, Y., Roth, M.-P., Nemeth, E., & Ganz, T. (2011) · Hepatology · doi:10.1002/hep.24178 · Cited by 238
Self-citationPreza, G. C., Ruchala, P., Pinon, R., Ramos, E., Qiao, B., Peralta, M. A., Sharma, S., Waring, A., Ganz, T., & Nemeth, E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57693 · Cited by 234
Self-citationHepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice
Gardenghi, S., Ramos, P., Marongiu, M. F., Melchiori, L., Breda, L., Guy, E., Muirhead, K., Rao, N., Roy, C. N., Andrews, N. C., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41717 · Cited by 220
Self-citation
Cited by
A Red carpet for iron metabolism
Muckenthaler, M. U., Rivella, S., Hentze, M. W., & Galy, B. (2017) · Cell · doi:10.1016/j.cell.2016.12.034 · Cited by 1,319
Ganz, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2013 · Cited by 1,122
Self-citationIdentification of erythroferrone as an erythroid regulator of iron metabolism
Kautz, L., Jung, G., Valore, E. V., Rivella, S., Nemeth, E., & Ganz, T. (2014) · Nature Genetics · doi:10.1038/ng.2996 · Cited by 1,127
Self-citationIron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Drakesmith, H., Nemeth, E., & Ganz, T. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.09.006 · Cited by 638
“The confidence in this model was reinforced by the rational design of 9-amino acid minihepcidins that were as potent as and more drug-like than hepcidin itself (Preza et al., 2011b; Ramos et al., 2012).”
BackgroundMethodSelf-citation
Metadata
- Authors
- Ramos, E., Ruchala, P., Goodnough, J. B., Kautz, L., Preza, G. C., Nemeth, E., & Ganz, T.
- Affiliations
- University of California, Los Angeles (US)
- University of Southern California (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-11-01
- Volume
- 120
- Issue
- 18
- Pages
- 3829-3836
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3488893
- OpenAlex
- W2023209642
- Cited by
- 213
- References
- 16
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 10 · 2023: 10 · 2022: 5 · 2021: 12 · 2020: 14 · 2019: 13 · 2018: 17 · 2017: 29 · 2016: 17 · 2015: 25 · 2014: 18 · 2013: 25 · 2012: 1
- FWCI
- 14.69
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000124)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK065029, R01DK090554)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- iron overload, hereditary hemochromatosis, iron absorption regulation, cardiac iron, spleen iron, phlebotomy, iron chelation
- MeSH terms
- Animals, Chromatography, High Pressure Liquid, Disease Models, Animal, Hemochromatosis, Male, Mice, Inbred C57BL, Mice, Knockout, Anemia, Iron-Deficiency, Iron Overload, Antimicrobial Cationic Peptides, Mice, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. https://app.cochat.ai/papers/10.1182/blood-2012-07-440743
- The paper
- Ramos, E., Ruchala, P., Goodnough, J. B., Kautz, L., Preza, G. C., Nemeth, E., & Ganz, T. (2012). Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood. https://doi.org/10.1182/blood-2012-07-440743
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.